Skip to main content
Top
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | SARS-CoV-2 | Research

Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

Authors: Inge Kroidl, Simon Winter, Raquel Rubio-Acero, Abhishek Bakuli, Christof Geldmacher, Tabea M. Eser, Flora Déak, Sacha Horn, Anna Zielke, Mohamed I. M. Ahmed, Paulina Diepers, Jessica Guggenbühl, Jonathan Frese, Jan Bruger, Kerstin Puchinger, Jakob Reich, Philine Falk, Alisa Markgraf, Heike Fensterseifer, Ivana Paunovic, Angelika Thomschke, Michael Pritsch, Friedrich Riess, Elmar Saathoff, Michael Hoelscher, Laura Olbrich, Noemi Castelletti, Andreas Wieser, KoCo19/ORCHESTRA Study Group

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Background

Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization between different quantitative anti-Spike assays to defined Binding Antibody Units (BAU).

Methods

To assess sero-responses longitudinally, a cohort of ninety-nine SARS-CoV-2 RT-PCR positive subjects was followed up together with forty-five vaccinees without previous infection but with two vaccinations. Sero-responses were evaluated using a total of six different assays: four measuring anti-Spike proteins (converted to BAU), one measuring anti-Nucleocapsid proteins and one SARS-CoV-2 surrogate virus neutralization. Both cohorts were evaluated using the Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and the Roche Elecsys Anti-SARS-CoV-2 anti-S1 assay.

Results

In SARS-CoV-2-convalesce subjects, the BAU-sero-responses of Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and Roche Elecsys Anti-SARS-CoV-2 anti-S1 peaked both at 47 (43–51) days, the first assay followed by a slow decay thereafter (> 208 days), while the second assay not presenting any decay within one year. Both assay values in BAUs are only equivalent a few months after infection, elsewhere correction factors up to 10 are necessary. In contrast, in infection-naive vaccinees the assays perform similarly.

Conclusion

The results of our study suggest that the establishment of a protective correlate or vaccination booster recommendation based on different assays, although BAU-standardised, is still challenging. At the moment the characteristics of the available assays used are not related, and the BAU-standardisation is unable to correct for that.
Appendix
Available only for authorised users
Literature
3.
go back to reference Lumley SF, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021;384(6):533–40.CrossRefPubMed Lumley SF, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021;384(6):533–40.CrossRefPubMed
4.
go back to reference Letizia AG, et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Med. 2021;9(7):712–20.CrossRefPubMedPubMedCentral Letizia AG, et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Med. 2021;9(7):712–20.CrossRefPubMedPubMedCentral
5.
go back to reference Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.CrossRefPubMed Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.CrossRefPubMed
6.
go back to reference Dagan N, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–23.CrossRefPubMed Dagan N, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–23.CrossRefPubMed
7.
go back to reference Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.CrossRefPubMed Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.CrossRefPubMed
8.
go back to reference Voysey M, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.CrossRefPubMedPubMedCentral Voysey M, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.CrossRefPubMedPubMedCentral
9.
go back to reference Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27(2):205–11.CrossRefPubMed Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27(2):205–11.CrossRefPubMed
10.
go back to reference Barros-Martins J, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021;27(9):1525–9.CrossRefPubMedPubMedCentral Barros-Martins J, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021;27(9):1525–9.CrossRefPubMedPubMedCentral
11.
go back to reference Caniels TG, et al. Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. Sci Adv. 2021;7(36):eabj5365.CrossRefPubMedPubMedCentral Caniels TG, et al. Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. Sci Adv. 2021;7(36):eabj5365.CrossRefPubMedPubMedCentral
12.
go back to reference Kroidl I, et al. Vaccine breakthrough infection and onward transmission of SARS-CoV-2 Beta (B.1.351) variant, Bavaria, Germany, February to March 2021. Euro Surveill. 2021;26(30):2100673.CrossRefPubMedPubMedCentral Kroidl I, et al. Vaccine breakthrough infection and onward transmission of SARS-CoV-2 Beta (B.1.351) variant, Bavaria, Germany, February to March 2021. Euro Surveill. 2021;26(30):2100673.CrossRefPubMedPubMedCentral
13.
go back to reference Hacisuleyman E, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021;384(23):2212–8.CrossRefPubMed Hacisuleyman E, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021;384(23):2212–8.CrossRefPubMed
15.
go back to reference Bergwerk M, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474–84.CrossRefPubMed Bergwerk M, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474–84.CrossRefPubMed
16.
go back to reference Long QX, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–8.CrossRefPubMed Long QX, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–8.CrossRefPubMed
17.
go back to reference Long QX, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200–4.CrossRefPubMed Long QX, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200–4.CrossRefPubMed
18.
go back to reference Ibarrondo FJ, et al. Rapid decay of Anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085–7.CrossRefPubMed Ibarrondo FJ, et al. Rapid decay of Anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085–7.CrossRefPubMed
19.
go back to reference Dan JM, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063.CrossRefPubMed Dan JM, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063.CrossRefPubMed
21.
go back to reference Ripperger TJ, et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity. Immunity. 2020;53(5):925–33.CrossRefPubMedPubMedCentral Ripperger TJ, et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity. Immunity. 2020;53(5):925–33.CrossRefPubMedPubMedCentral
22.
go back to reference Harris RJ, et al. Serological surveillance of SARS-CoV-2: six-month trends and antibody response in a cohort of public health workers. J Infect. 2021;82(5):162–9.CrossRefPubMedPubMedCentral Harris RJ, et al. Serological surveillance of SARS-CoV-2: six-month trends and antibody response in a cohort of public health workers. J Infect. 2021;82(5):162–9.CrossRefPubMedPubMedCentral
23.
go back to reference Olbrich L, et al. (2021) Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2. J Gen Virol. 2021;102(10):001653.CrossRefPubMedPubMedCentral Olbrich L, et al. (2021) Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2. J Gen Virol. 2021;102(10):001653.CrossRefPubMedPubMedCentral
29.
go back to reference Characterisation WHOWGotC, Management of C-I. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020; 20(8): e192–7. Characterisation WHOWGotC, Management of C-I. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020; 20(8): e192–7.
30.
go back to reference Puchinger K, et al. The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2: results from a prospective cohort of outpatient COVID-19 cases. Virology. 2022;569:37–43.CrossRefPubMed Puchinger K, et al. The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2: results from a prospective cohort of outpatient COVID-19 cases. Virology. 2022;569:37–43.CrossRefPubMed
31.
go back to reference Rubio-Acero R, et al. In search of the SARS-CoV-2 protection correlate: head-to-head comparison of two quantitative S1 assays in pre-characterized oligo-/asymptomatic patients. Infect Dis Ther. 2021;7:491. Rubio-Acero R, et al. In search of the SARS-CoV-2 protection correlate: head-to-head comparison of two quantitative S1 assays in pre-characterized oligo-/asymptomatic patients. Infect Dis Ther. 2021;7:491.
32.
go back to reference Favresse J, et al. Persistence of anti-SARS-CoV-2 antibodies depends on the analytical kit: a report for up to 10 months after infection. Microorganisms. 2021;9(3):556.CrossRefPubMedPubMedCentral Favresse J, et al. Persistence of anti-SARS-CoV-2 antibodies depends on the analytical kit: a report for up to 10 months after infection. Microorganisms. 2021;9(3):556.CrossRefPubMedPubMedCentral
33.
go back to reference Muecksch F, et al. Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients. J Infect Dis. 2021;223(3):389–98.CrossRefPubMed Muecksch F, et al. Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients. J Infect Dis. 2021;223(3):389–98.CrossRefPubMed
34.
35.
go back to reference Figueiredo-Campos P, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. Eur J Immunol. 2020;50(12):2025–40.CrossRefPubMedPubMedCentral Figueiredo-Campos P, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. Eur J Immunol. 2020;50(12):2025–40.CrossRefPubMedPubMedCentral
36.
go back to reference Seow J, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598–607.CrossRefPubMedPubMedCentral Seow J, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598–607.CrossRefPubMedPubMedCentral
37.
go back to reference Gudbjartsson DF, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724–34.CrossRefPubMed Gudbjartsson DF, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724–34.CrossRefPubMed
38.
go back to reference Roltgen K, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5(54):eabe0240.CrossRefPubMedPubMedCentral Roltgen K, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5(54):eabe0240.CrossRefPubMedPubMedCentral
39.
go back to reference Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med. 2021;27(7):1147–8.CrossRefPubMed Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med. 2021;27(7):1147–8.CrossRefPubMed
41.
go back to reference Haas EJ, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–29.CrossRefPubMedPubMedCentral Haas EJ, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–29.CrossRefPubMedPubMedCentral
43.
go back to reference Tang P, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27(12):2136–43.CrossRefPubMed Tang P, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27(12):2136–43.CrossRefPubMed
44.
go back to reference Levin EG, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.CrossRefPubMed Levin EG, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.CrossRefPubMed
45.
go back to reference Chemaitelly H, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385(24):e83.CrossRefPubMed Chemaitelly H, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385(24):e83.CrossRefPubMed
46.
go back to reference Feikin DR, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–44.CrossRefPubMedPubMedCentral Feikin DR, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–44.CrossRefPubMedPubMedCentral
47.
go back to reference Scheiblauer H, et al. Antibody response to SARS-CoV-2 for more than one year: kinetics and persistence of detection are predominantly determined by avidity progression and test design. J Clin Virol. 2022;146:105052.CrossRefPubMed Scheiblauer H, et al. Antibody response to SARS-CoV-2 for more than one year: kinetics and persistence of detection are predominantly determined by avidity progression and test design. J Clin Virol. 2022;146:105052.CrossRefPubMed
Metadata
Title
Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison
Authors
Inge Kroidl
Simon Winter
Raquel Rubio-Acero
Abhishek Bakuli
Christof Geldmacher
Tabea M. Eser
Flora Déak
Sacha Horn
Anna Zielke
Mohamed I. M. Ahmed
Paulina Diepers
Jessica Guggenbühl
Jonathan Frese
Jan Bruger
Kerstin Puchinger
Jakob Reich
Philine Falk
Alisa Markgraf
Heike Fensterseifer
Ivana Paunovic
Angelika Thomschke
Michael Pritsch
Friedrich Riess
Elmar Saathoff
Michael Hoelscher
Laura Olbrich
Noemi Castelletti
Andreas Wieser
KoCo19/ORCHESTRA Study Group
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02167-z

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine